

PRIOR AUTHORIZATION REQUEST FORM

Symdeko

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

	Prescriber Name:		
Patient Name:	Supervising Physician:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if	Specialty/facility name (if applicable):	
Drug Name and Strength:			
Directions / SIG:			
Please attach any pertinent medical history or fo	information for this patient that may llowing questions and sign.	support approval. Please answer the	
Q1. What diagnosis is this drug being prescribed	d for?		
☐ Cystic Fibrosis	Other (Please Specify)		
Q2. Please provide ICD code(s) for diagnosis			
Q3. Please provide most recent chart note, labs for the pharmacist and medical director reviewin confirm all criteria are met.		•	
Q4. Is patient a NEW START to Symdeko thera	py?		
Yes	☐ No - provide sta	art date	
Q5. Please select all that apply regarding the C	TFR gene:		
☐ Confirmed homozygous F508del mutation gene using an FDA-approved test	n on the cystic fibrosis transmembr	ane conductance regulator (CFTR)	
☐ At least one mutation in the CFTR gene to clinical evidence	hat is responsive to tezacaftor/ivac	aftor based on in vitro data and/or	



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Symdeko

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

	Prescriber Name:
Patient Name:	Supervising Physician:
☐ None of the above	
Q6. Please select all that apply regarding labs and provide AST/ALT < 5 x ULN AST/ALT < 3 x ULN if bilirubin is > 2 x ULN None of the above	documentation:
Q7. If the patient is between the age of 12 to 18 years of a ophthalmic exam(s) to check for lens opacities and cataracters. Yes No No N/A (Patient >18 years)	
Q8. Will the patient be taking any of the following medication: Kalydeco Orkambi Strong CYP3A4 inducers (e.g. barbiturates, carbamaze oxcarbamazepine, phenobarbital, phenytoin, pioglitazone, None of the Above	epine, efavirenz, glucocorticoids, modafinil, nevirapine,
Q9. If request is for CONTINUATION of therapy, is patient therapy?	's FEV1 stable or has it improved since initiation of
☐ Yes	□ No
Q10. If request is for CONTINUATION of therapy, does pa of therapy?	tient have a documented clinical improvement since initiation
☐ Yes	□ No
Q11. Additional Comments	



PRIOR AUTHORIZATION REQUEST FORM **EOC ID:**

Symdeko

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review

blank or illegible may delay the review process.	g questions and fax this form to the	number listed above. Please note any information left	
Patient Name:	Prescriber Name:		
	Supervising Physician:		
Prescriber Signature		Date	
□ Expedited/Urgent - By checking this box and seriously jeopardize the life or health of the enr			
Lack of the necessary documentation may result in a or medical director at 1-800-728-7947 regarding the has been decided.	-		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document